EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark

Theis Skovsgaard Itenov iD, Anthony D Bai, Tor Biering-Sørensen, Amol Verma, Fahad Razak, Ajay Bhasin, Henning Bundgaard, Pradeesh Sivapalan, Kasper Iversen, Christian Rasmussen, Jens Rasmussen, Lotte Klitfod und 3 weitere

Pharmacoepidemiology and Drug Safety · 2025-06 · 34 (6)

DOI: 10.1002/pds.70163 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 07.06.2025. Verfasst von Theis Skovsgaard Itenov und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azithromycin, Cardiovascular Diseases, Clarithromycin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies suggest that clarithromycin is associated with an increased risk of major adverse cardiovascular events (MACE) among adults with coronary artery disease. However, data comparing clarithromycin to other macrolides, such as azithromycin, in a broader population are lacking.

Methods

A multicenter study was conducted in 33 hospitals in Ontario, Canada, and Copenhagen, Denmark, using the Target Trial framework. Adults hospitalized with community‐acquired pneumonia (CAP) who received either clarithromycin or azithromycin were included. The primary outcome was MACE, defined as the one‐year risk of nonfatal myocardial infarction, nonfatal stroke, or all‐cause mortality. Propensity score matching and Cox proportional hazards models were used for analysis.

Results

In Ontario, we identified 23 081 patients with CAP, and 11 164 received oral macrolides. After propensity score matching, the primary outcome occurred in 7.8% of clarithromycin patients and 9.1% of azithromycin patients (HR 0.85, 95% CI 0.60–1.21). In Copenhagen, there were 11 280 patients with CAP and 3924 received oral macrolides. After propensity score matching, 19% of clarithromycin patients and 12% of azithromycin patients experienced the primary outcome for oral macrolides (HR 1.7, 95% CI 1.2–2.4, p = 0.002). Meta‐analysis of the point estimate from each country provided an overall HR of 1.21 (95% CI 0.61–2.39). For intravenous macrolides in Copenhagen, the HR was 1.15 (95% CI 1.0–1.3, p = 0.007) for clarithromycin compared to azithromycin.

Conclusion

This study did not consistently observe an increased risk of cardiovascular events with clarithromycin among adults hospitalized with CAP. However, the observational nature of the study may introduce selection bias and unmeasured confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzithromycinCardiovascular DiseasesClarithromycinCommunity-Acquired InfectionsPneumoniaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCanadaCohort StudiesCommunity-Acquired PneumoniaDenmarkPropensity Score

Stichwörter der Autor:innen

cardiovacular complicationscommunity‐acquired pneumoniamacrolides

Substanzen

Anti-Bacterial AgentsAzithromycinClarithromycin

Autor:innen und Institutionen

  • Department of Anesthesiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Faculty of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Theis Skovsgaard Itenov, Mike Fralick

Zitieren

APA

Itenov, T. S., Bai, A. D., Biering-Sørensen, T., Verma, A., Razak, F., Bhasin, A., Bundgaard, H., Sivapalan, P., Iversen, K., Rasmussen, C., Rasmussen, J., Klitfod, L., Dircks, K., Jensen, J. S., & Fralick, M. (2025). Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark. Pharmacoepidemiology and Drug Safety, 34(6). https://doi.org/10.1002/pds.70163

Vancouver

Itenov TS, Bai AD, Biering-Sørensen T, Verma A, Razak F, Bhasin A, et al. Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark. Pharmacoepidemiology and Drug Safety. 2025;34(6). doi:10.1002/pds.70163

BibTeX
@article{Itenov2025,
  author = {Itenov, Theis Skovsgaard and Bai, Anthony D and Biering-Sørensen, Tor and Verma, Amol and Razak, Fahad and Bhasin, Ajay and Bundgaard, Henning and Sivapalan, Pradeesh and Iversen, Kasper and Rasmussen, Christian and Rasmussen, Jens and Klitfod, Lotte and Dircks, Kathrine and Jensen, Jens-Ulrik S and Fralick, Mike},
  title = {Clarithromycin Versus Azithromycin for Community‐Acquired Pneumonia and the Risk of Major Adverse Cardiovascular Events: A Multicentre Cohort Study Using Data From Canada and Denmark},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  volume = {34},
  number = {6},
  doi = {10.1002/pds.70163}
}
Kostenlos starten →